362 related articles for article (PubMed ID: 35032437)
1. Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial.
Cella D; Motzer RJ; Suarez C; Blum SI; Ejzykowicz F; Hamilton M; Wallace JF; Simsek B; Zhang J; Ivanescu C; Apolo AB; Choueiri TK
Lancet Oncol; 2022 Feb; 23(2):292-303. PubMed ID: 35032437
[TBL] [Abstract][Full Text] [Related]
2. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial.
Cella D; Grünwald V; Escudier B; Hammers HJ; George S; Nathan P; Grimm MO; Rini BI; Doan J; Ivanescu C; Paty J; Mekan S; Motzer RJ
Lancet Oncol; 2019 Feb; 20(2):297-310. PubMed ID: 30658932
[TBL] [Abstract][Full Text] [Related]
3. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.
Motzer RJ; Powles T; Burotto M; Escudier B; Bourlon MT; Shah AY; Suárez C; Hamzaj A; Porta C; Hocking CM; Kessler ER; Gurney H; Tomita Y; Bedke J; Zhang J; Simsek B; Scheffold C; Apolo AB; Choueiri TK
Lancet Oncol; 2022 Jul; 23(7):888-898. PubMed ID: 35688173
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Choueiri TK; Powles T; Burotto M; Escudier B; Bourlon MT; Zurawski B; Oyervides Juárez VM; Hsieh JJ; Basso U; Shah AY; Suárez C; Hamzaj A; Goh JC; Barrios C; Richardet M; Porta C; Kowalyszyn R; Feregrino JP; Żołnierek J; Pook D; Kessler ER; Tomita Y; Mizuno R; Bedke J; Zhang J; Maurer MA; Simsek B; Ejzykowicz F; Schwab GM; Apolo AB; Motzer RJ;
N Engl J Med; 2021 Mar; 384(9):829-841. PubMed ID: 33657295
[TBL] [Abstract][Full Text] [Related]
5. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.
Motzer RJ; Rini BI; McDermott DF; Arén Frontera O; Hammers HJ; Carducci MA; Salman P; Escudier B; Beuselinck B; Amin A; Porta C; George S; Neiman V; Bracarda S; Tykodi SS; Barthélémy P; Leibowitz-Amit R; Plimack ER; Oosting SF; Redman B; Melichar B; Powles T; Nathan P; Oudard S; Pook D; Choueiri TK; Donskov F; Grimm MO; Gurney H; Heng DYC; Kollmannsberger CK; Harrison MR; Tomita Y; Duran I; Grünwald V; McHenry MB; Mekan S; Tannir NM;
Lancet Oncol; 2019 Oct; 20(10):1370-1385. PubMed ID: 31427204
[TBL] [Abstract][Full Text] [Related]
6. Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial.
Cella D; Grünwald V; Nathan P; Doan J; Dastani H; Taylor F; Bennett B; DeRosa M; Berry S; Broglio K; Berghorn E; Motzer RJ
Lancet Oncol; 2016 Jul; 17(7):994-1003. PubMed ID: 27283863
[TBL] [Abstract][Full Text] [Related]
7. Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study.
Motzer R; Porta C; Alekseev B; Rha SY; Choueiri TK; Mendez-Vidal MJ; Hong SH; Kapoor A; Goh JC; Eto M; Bennett L; Wang J; Pan JJ; Saretsky TL; Perini RF; He CS; Mody K; Cella D
Lancet Oncol; 2022 Jun; 23(6):768-780. PubMed ID: 35489363
[TBL] [Abstract][Full Text] [Related]
8. Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma.
Geynisman DM; Burotto M; Porta C; Suarez C; Bourlon MT; Huo S; Del Tejo V; Du EX; Yang X; Betts KA; Choueiri TK; McGregor B
Clin Drug Investig; 2022 Jul; 42(7):611-622. PubMed ID: 35696045
[TBL] [Abstract][Full Text] [Related]
9. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial.
Powles T; Plimack ER; Soulières D; Waddell T; Stus V; Gafanov R; Nosov D; Pouliot F; Melichar B; Vynnychenko I; Azevedo SJ; Borchiellini D; McDermott RS; Bedke J; Tamada S; Yin L; Chen M; Molife LR; Atkins MB; Rini BI
Lancet Oncol; 2020 Dec; 21(12):1563-1573. PubMed ID: 33284113
[TBL] [Abstract][Full Text] [Related]
10. Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial.
Reck M; Schenker M; Lee KH; Provencio M; Nishio M; Lesniewski-Kmak K; Sangha R; Ahmed S; Raimbourg J; Feeney K; Corre R; Franke FA; Richardet E; Penrod JR; Yuan Y; Nathan FE; Bhagavatheeswaran P; DeRosa M; Taylor F; Lawrance R; Brahmer J
Eur J Cancer; 2019 Jul; 116():137-147. PubMed ID: 31195357
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
[TBL] [Abstract][Full Text] [Related]
12. Cabozantinib plus Nivolumab: A Review in Advanced Renal Cell Carcinoma.
Markham A
Target Oncol; 2022 Mar; 17(2):193-201. PubMed ID: 35175500
[TBL] [Abstract][Full Text] [Related]
13. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial.
Pal SK; Tangen C; Thompson IM; Balzer-Haas N; George DJ; Heng DYC; Shuch B; Stein M; Tretiakova M; Humphrey P; Adeniran A; Narayan V; Bjarnason GA; Vaishampayan U; Alva A; Zhang T; Cole S; Plets M; Wright J; Lara PN
Lancet; 2021 Feb; 397(10275):695-703. PubMed ID: 33592176
[TBL] [Abstract][Full Text] [Related]
14. A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma.
McGregor B; Geynisman DM; Burotto M; Suárez C; Bourlon MT; Barata PC; Gulati S; Huo S; Ejzykowicz F; Blum SI; Del Tejo V; Hamilton M; May JR; Du EX; Wu A; Kral P; Ivanescu C; Chin A; Betts KA; Lee CH; Choueiri TK; Cella D; Porta C
Eur Urol Oncol; 2023 Jun; 6(3):339-348. PubMed ID: 36842942
[TBL] [Abstract][Full Text] [Related]
15. First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes.
Reck M; Ciuleanu TE; Cobo M; Schenker M; Zurawski B; Menezes J; Richardet E; Bennouna J; Felip E; Juan-Vidal O; Alexandru A; Cheng Y; Sakai H; Paz-Ares L; Lu S; John T; Sun X; Moisei A; Taylor F; Lawrance R; Zhang X; Sylvester J; Yuan Y; Blum SI; Penrod JR; Carbone DP
Eur J Cancer; 2023 Apr; 183():174-187. PubMed ID: 36871487
[TBL] [Abstract][Full Text] [Related]
16. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
Motzer RJ; Tannir NM; McDermott DF; Arén Frontera O; Melichar B; Choueiri TK; Plimack ER; Barthélémy P; Porta C; George S; Powles T; Donskov F; Neiman V; Kollmannsberger CK; Salman P; Gurney H; Hawkins R; Ravaud A; Grimm MO; Bracarda S; Barrios CH; Tomita Y; Castellano D; Rini BI; Chen AC; Mekan S; McHenry MB; Wind-Rotolo M; Doan J; Sharma P; Hammers HJ; Escudier B;
N Engl J Med; 2018 Apr; 378(14):1277-1290. PubMed ID: 29562145
[TBL] [Abstract][Full Text] [Related]
17. Cabozantinib exposure-response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma.
Tran BD; Li J; Ly N; Faggioni R; Roskos L
Cancer Chemother Pharmacol; 2023 Feb; 91(2):179-189. PubMed ID: 36625894
[TBL] [Abstract][Full Text] [Related]
18. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.
Choueiri TK; Escudier B; Powles T; Tannir NM; Mainwaring PN; Rini BI; Hammers HJ; Donskov F; Roth BJ; Peltola K; Lee JL; Heng DYC; Schmidinger M; Agarwal N; Sternberg CN; McDermott DF; Aftab DT; Hessel C; Scheffold C; Schwab G; Hutson TE; Pal S; Motzer RJ;
Lancet Oncol; 2016 Jul; 17(7):917-927. PubMed ID: 27279544
[TBL] [Abstract][Full Text] [Related]
19. Exposure-Response Analysis to Support Nivolumab Once Every 4 Weeks Dosing in Combination with Cabozantinib in Renal Cell Carcinoma.
Hamuro L; Hu Z; Passarell J; Barcomb H; Zhang J; Goldstein S; Bello A; Roy A; Zhu L
Clin Cancer Res; 2022 Apr; 28(8):1603-1613. PubMed ID: 34980597
[TBL] [Abstract][Full Text] [Related]
20. Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial.
Cella D; Escudier B; Tannir NM; Powles T; Donskov F; Peltola K; Schmidinger M; Heng DYC; Mainwaring PN; Hammers HJ; Lee JL; Roth BJ; Marteau F; Williams P; Baer J; Mangeshkar M; Scheffold C; Hutson TE; Pal S; Motzer RJ; Choueiri TK
J Clin Oncol; 2018 Mar; 36(8):757-764. PubMed ID: 29377755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]